Kidney injury biomarkers in hypertensive, diabetic, and nephropathy rat models treated with contrast media.
Dietary acid reduction with fruits and vegetables or bicarbonate attenuates kidney injury in patients with a moderately reduced glomerular filtration rate due to hypertensive nephropathy.
Oxidative Stress in Kidney Injury and Hypertension.
Arendshorst WJ, Vendrov AE, Kumar N, Ganesh SK, Madamanchi NR.
Antioxidants (Basel). 2024 Nov 27;13(12):1454. doi: 10.3390/antiox13121454.
Molecular Mechanisms of Hypertensive Nephropathy: Renoprotective Effect of Losartan through Hsp70.
Costantino VV, Gil Lorenzo AF, Bocanegra V, Vallés PG.
Cells. 2021 Nov 12;10(11):3146. doi: 10.3390/cells10113146.
Natural products: potential treatments for cisplatin-induced nephrotoxicity.
Fang CY, Lou DY, Zhou LQ, Wang JC, Yang B, He QJ, Wang JJ, Weng QJ.
Acta Pharmacol Sin. 2021 Dec;42(12):1951-1969. doi: 10.1038/s41401-021-00620-9. Epub 2021 Mar 9.
OTUD1 promotes hypertensive kidney fibrosis and injury by deubiquitinating CDK9 in renal epithelial cells.
Wang MY, Yu TX, Wang QY, Han X, Hu X, Ye SJ, Long XH, Wang Y, Zhu H, Luo W, Liang G.
Acta Pharmacol Sin. 2024 Apr;45(4):765-776. doi: 10.1038/s41401-023-01192-6. Epub 2023 Dec 18.
Epigenetics of Hypertensive Nephropathy.
Zhang Y, Arzaghi H, Ma Z, Roye Y, Musah S.
Biomedicines. 2024 Nov 16;12(11):2622. doi: 10.3390/biomedicines12112622.
Deacetylation of Septin4 by SIRT2 (Silent Mating Type Information Regulation 2 Homolog-2) Mitigates Damaging of Hypertensive Nephropathy.
Zhang Y, Zhang N, Zou Y, Song C, Cao K, Wu B, You S, Lu S, Wang D, Xu J, Huang X, Zhang P, Fan Z, Liu J, Cheng Z, Zhang Z, Kong C, Cao L, Sun Y.
Circ Res. 2023 Mar 3;132(5):601-624. doi: 10.1161/CIRCRESAHA.122.321591. Epub 2023 Feb 14.
Roles of the mechanosensitive ion channel Piezo1 in the renal podocyte injury of experimental hypertensive nephropathy.
Ogino S, Yoshikawa K, Nagase T, Mikami K, Nagase M.
Hypertens Res. 2024 Mar;47(3):747-759. doi: 10.1038/s41440-023-01536-z. Epub 2023 Dec 25.
Inhibition of ferroptosis ameliorates hypertensive nephropathy through p53/Nrf2/p21 pathway by Taohongsiwu decoction: Based on network pharmacology and experimental validation.
Xie T, Bai Z, Chen Z, Liang H, Liu T, Lam LK, Xu P, Xie P, Chen L, Xiao Y.
J Ethnopharmacol. 2023 Aug 10;312:116506. doi: 10.1016/j.jep.2023.116506. Epub 2023 Apr 21.
GPR97 deficiency ameliorates renal interstitial fibrosis in mouse hypertensive nephropathy.
Wu JC, Wang XJ, Zhu JH, Huang XY, Liu M, Qiao Z, Zhang Y, Sun Y, Wang ZY, Zhan P, Zhang T, Hu HL, Liu H, Tang W, Yi F.
Acta Pharmacol Sin. 2023 Jun;44(6):1206-1216. doi: 10.1038/s41401-022-01041-y. Epub 2023 Jan 12.
GSDMD Mediates Ang II-Induced Hypertensive Nephropathy by Regulating the GATA2/AQP4 Signaling Pathway.
Fan X, Zhang W, Zheng R, Zhang Y, Lai X, Han J, Fang Z, Han B, Huang W, Ye B, Dai S.
J Inflamm Res. 2024 Nov 5;17:8241-8259. doi: 10.2147/JIR.S488553. eCollection 2024.
